Nanomedicine for brain cancer
CNS tumors remain among the deadliest forms of cancer, resisting conventional and new
treatment approaches, with mortality rates staying practically unchanged over the past 30 …
treatment approaches, with mortality rates staying practically unchanged over the past 30 …
[HTML][HTML] CAR T cell-based immunotherapy for the treatment of glioblastoma
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumor in adults. Current treatment options typically consist of surgery followed by …
tumor in adults. Current treatment options typically consist of surgery followed by …
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
Immunotherapy with anti-GD2 antibodies has advanced the treatment of children with high-
risk neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms …
risk neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms …
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma
LK Donovan, A Delaidelli, SK Joseph, K Bielamowicz… - Nature medicine, 2020 - nature.com
Recurrent medulloblastoma and ependymoma are universally lethal, with no approved
targeted therapies and few candidates presently under clinical evaluation. Nearly all …
targeted therapies and few candidates presently under clinical evaluation. Nearly all …
CAR T cells for brain tumors: Lessons learned and road ahead
Malignant brain tumors, including glioblastoma, represent some of the most difficult to treat
of solid tumors. Nevertheless, recent progress in immunotherapy, across a broad range of …
of solid tumors. Nevertheless, recent progress in immunotherapy, across a broad range of …
CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies
Glioblastoma (GBM) contains self-renewing GBM stem cells (GSC) potentially amenable to
immunologic targeting, but chimeric antigen receptor (CAR) T-cell therapy has demonstrated …
immunologic targeting, but chimeric antigen receptor (CAR) T-cell therapy has demonstrated …
CAR T cell therapy in primary brain tumors: current investigations and the future
YJ Lin, LA Mashouf, M Lim - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T cells (CAR T cells) are engineered cells expressing a chimeric
antigen receptor (CAR) against a specific tumor antigen (TA) that allows for the identification …
antigen receptor (CAR) against a specific tumor antigen (TA) that allows for the identification …
Advances in immunotherapy for glioblastoma multiforme
AB Mahmoud, R Ajina, S Aref, M Darwish… - Frontiers in …, 2022 - frontiersin.org
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor
of the central nervous system and has a very poor prognosis. The current standard of care …
of the central nervous system and has a very poor prognosis. The current standard of care …
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
Diffuse midline gliomas (DMGs) are universally lethal malignancies occurring chiefly during
childhood and involving midline structures of the central nervous system, including …
childhood and involving midline structures of the central nervous system, including …
Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy
Synthetic immunity to cancer has been pioneered by the application of chimeric antigen
receptor (CAR) engineering into autologous T cells. CAR T cell therapy is highly amenable …
receptor (CAR) engineering into autologous T cells. CAR T cell therapy is highly amenable …